UPB (Upstream Bio) Debt-to-EBITDA : -0.02 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Upstream Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.70 Mil. Upstream Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $1.13 Mil. Upstream Bio's annualized EBITDA for the quarter that ended in Dec. 2024 was $-105.08 Mil. Upstream Bio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Upstream Bio's Debt-to-EBITDA or its related term are showing as below:

UPB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.04 Med: 0 Max: 0
Current: -0.04

UPB's Debt-to-EBITDA is ranked worse than
100% of 281 companies
in the Biotechnology industry
Industry Median: 1.54 vs UPB: -0.04

Upstream Bio Debt-to-EBITDA Historical Data

The historical data trend for Upstream Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Debt-to-EBITDA Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Debt-to-EBITDA

-0.02

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Debt-to-EBITDA	Get a 7-Day Free Trial			-	-	N/A	-0.03	-0.02

Competitive Comparison of Upstream Bio's Debt-to-EBITDA

For the Biotechnology subindustry, Upstream Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Upstream Bio's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Upstream Bio's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Upstream Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Upstream Bio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.704	+	1.13)	/	-77.675
	=	-0.02

Upstream Bio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.704	+	1.13)	/	-105.076
	=	-0.02

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.

Upstream Bio (NAS:UPB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Upstream Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.